{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:59:53Z","timestamp":1762430393744,"version":"3.37.3"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T00:00:00Z","timestamp":1251936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000885","name":"Children's Cancer Research Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000885","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2009,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Allogeneic hematopoietic cell transplant (HCT) with best available donor for children with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) has previously been considered standard practice. Since the introduction of imatinib into the treatment of this disease, the role of allogeneic HCT is more uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>We investigated the impact of remission status, graft source, and imatinib use on transplant outcomes for 37 children with Ph+ ALL who received an allogeneic HCT at the University of Minnesota between 1990 and 2006. The median age at HCT was 7.47 (range; 1.4\u201316.4) years. Thirteen patients received imatinib therapy pre\u2010 and\/or post\u2010HCT (imatinib group) and 24 patients, received either no imatinib (n\u2009=\u200923) or only post\u2010HCT relapse (n\u2009=\u20091) (non\u2010imatinib group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no difference in disease\u2010free survival (DFS) or relapse between the imatinib and non\u2010imatinib groups at 3 years (62%\/15% vs. 53%\/26%; <jats:italic>P<\/jats:italic>\u2009=\u20090.99; 0.81, respectively). There was no significant difference in transplant outcomes between matched related donor or unrelated donor (umbilical cord blood or matched unrelated marrow) recipients whereas patients receiving allogeneic HCT in first remission (CR1) had superior DFS and less relapse compared to patients transplanted in \u2265CR2 (71%\/16% vs. 29%\/36%; <jats:italic>P<\/jats:italic>\u2009=\u20090.01; <jats:italic>P<\/jats:italic>\u2009=\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on this retrospective analysis at a single institution, the use of imatinib either pre\u2010 and\/or post\u2010transplant does not appear to significantly impact outcomes for children with Ph+ ALL and allogeneic HCT with the best available donor should be encouraged in CR1. Pediatr Blood Cancer 2009; 53:1289\u20131294. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22263","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T15:57:13Z","timestamp":1251993433000},"page":"1289-1294","source":"Crossref","is-referenced-by-count":25,"title":["Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome\u2010positive acute lymphoblastic leukemia (ALL)"],"prefix":"10.1002","volume":"53","author":[{"given":"Michael J.","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barb","family":"Trotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_6_5_2","first-page":"2730","article-title":"Philadelphia chromosome\u2010positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome","volume":"92","author":"Schrappe M","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1225"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3032"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3785"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2177"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood.V110.11.4.4","article-title":"Improved early event free survival (EFS) in children with Philadelphia chromosome\u2010positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031","volume":"110","author":"Schultz KR","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.296"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400749"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.441"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402526"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2958"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1389"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood.V110.11.8.8","article-title":"Does imatinib change the outcome in Philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII\/ECOG2993 Study","volume":"110","author":"Fielding AK","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11525"},{"key":"e_1_2_6_20_2","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant\u2010related mortality","volume":"91","author":"Deininger M","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06582.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-031682"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019836"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-3182fje"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419603"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060196"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802668881"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2527"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0069"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0508-494"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1335"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.130"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010802016557"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22263","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T23:10:36Z","timestamp":1697670636000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,3]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,12,15]]}},"alternative-id":["10.1002\/pbc.22263"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22263","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"type":"print","value":"1545-5009"},{"type":"electronic","value":"1545-5017"}],"subject":[],"published":{"date-parts":[[2009,9,3]]}}}